Patents by Inventor Maximiliane Koenig
Maximiliane Koenig has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).
-
Patent number: 11685790Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: August 11, 2021Date of Patent: June 27, 2023Assignee: Hoffmann-La Roche Inc.Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
-
Patent number: 11486882Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.Type: GrantFiled: May 20, 2019Date of Patent: November 1, 2022Assignee: HOFFMANN-LA ROCHE INC.Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
-
Publication number: 20220049020Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.Type: ApplicationFiled: April 6, 2021Publication date: February 17, 2022Inventors: Joerg Thomas REGULA, Stefan SEEBER, Wolfgang SCHAEFER, Sabine IMHOF-JUNG, Michael MOLHOJ, Maximiliane KOENIG, Peter BRUENKER, Christian KLEIN
-
Publication number: 20220041747Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: August 11, 2021Publication date: February 10, 2022Applicant: Hoffmann-La Roche Inc.Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
-
Patent number: 11214622Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: March 6, 2018Date of Patent: January 4, 2022Assignee: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
-
Patent number: 11180571Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: GrantFiled: September 30, 2019Date of Patent: November 23, 2021Assignee: Hoffmann-La Roche Inc.Inventors: Thomas Hofer, Maximiliane Koenig, Ekkehard Moessner, Jens Niewoehner, Tina Weinzierl, Laurent Lariviere
-
Publication number: 20210041163Abstract: Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index) and at positions 180-97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.Type: ApplicationFiled: July 27, 2020Publication date: February 11, 2021Inventors: Hubert KETTENBERG, Maximiliane KOENIG, Tilman SCHLOTHAUER, Pernille FOGED JENSEN, Kasper RAND
-
Publication number: 20200190212Abstract: The present invention generally relates to antibodies that bind to STEAP-1, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.Type: ApplicationFiled: September 30, 2019Publication date: June 18, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Thomas HOFER, Maximiliane KOENIG, Ekkehard MOESSNER, Jens NIEWOEHNER, Tina WEINZIERL, Laurent LARIVIERE
-
Publication number: 20200103413Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.Type: ApplicationFiled: May 20, 2019Publication date: April 2, 2020Applicant: Hoffmann-La Roche Inc.Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
-
Publication number: 20190062453Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: March 6, 2018Publication date: February 28, 2019Applicant: Roche Glycart AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, lnja Waldhauer, Huisheng Wang, Barbara Weiser
-
Patent number: 9926379Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: April 1, 2014Date of Patent: March 27, 2018Assignee: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser
-
Publication number: 20170211876Abstract: Herein is reported a method for selecting a full length antibody comprising the steps of a) generating from a parent full length antibody a plurality of full length antibodies by randomizing one or more amino acid residues selected from the amino acid residues at positions 1-23 in the heavy chain variable domain (numbering according to Kabat), at positions 55-83 in the light chain variable domain (numbering according to Kabat), at positions 145-174 in the first heavy chain constant domain (numbering according to EU index), and at positions 180-97 in the first heavy chain constant domain (numbering according to EU index), b) determining the binding strength of each of the full length antibodies from the 10 plurality of antibodies to the human neonatal Fc receptor (FcRn), and c) selecting a full length antibody from the plurality of full length antibodies that has a different binding strength to the FcRn than the parent full length antibody.Type: ApplicationFiled: June 10, 2015Publication date: July 27, 2017Inventors: Hubert KETTENBERGER, Maximiliane KOENIG, Tilman SCHLOTHAUER, Pernille FOGED JENSEN, Kasper RAND
-
Patent number: 9714292Abstract: The present invention relates to Bispecific antibodies against human TWEAK and human IL17 (bispecific TWEAK-IL17 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: GrantFiled: October 3, 2014Date of Patent: July 25, 2017Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Auer, Martin Bader, Jens Fischer, Hubert Kettenberger, Maximiliane Koenig, Stefan Lorenz, Joerg Moelleken
-
Publication number: 20170145116Abstract: The present invention relates to novel tetravalent multispecific antibodies, their manufacture and use.Type: ApplicationFiled: September 30, 2016Publication date: May 25, 2017Applicant: Hoffmann-La Roche Inc.Inventors: JOERG THOMAS REGULA, STEFAN SEEBER, WOLFGANG SCHAEFER, SABINE IMHOF-JUNG, MICHAEL MOLHOJ, MAXIMILIANE KOENIG, PETER BRUENKER, CHRISTIAN KLEIN
-
Publication number: 20170115304Abstract: Use of a limited digestion with a proteolytic enzyme of a multispecific antibody for the analysis of the multispecific antibody's light chain pairing.Type: ApplicationFiled: September 28, 2016Publication date: April 27, 2017Applicant: Hoffmann-La Roche Inc.Inventors: Michael Molhoj, Maximiliane Koenig, Vincent Larraillet, Katja Montan, Bianca Gruenwalder
-
Publication number: 20140370019Abstract: The present invention relates to bispecific antibodies comprising at least one antigen binding site specific for DR5 and at least one antigen binding site specific for FAP, antibodies specific for DR5, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.Type: ApplicationFiled: April 1, 2014Publication date: December 18, 2014Applicant: ROCHE GLYCART AGInventors: Peter Bruenker, Sherif Daouti, Ningping Feng, Claudia Ferrara Koller, Guy Georges, Sandra Grau-Richards, Ralf Hosse, Christian Klein, Maximiliane Koenig, Joerg Moelleken, Ekkehard Moessner, Huifeng Niu, Kathryn E. Packman, Valeria Runza, Stefan Seeber, Pablo Umana, Inja Waldhauer, Huisheng Wang, Barbara Weiser